Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain

Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain

Carmen Peral,1 Francisco Sánchez-Ballester,2 José M García-Mediero,3 Jaime Ramos,1 Javier Rejas1 1Health Economics & Outcomes Research Department, Pfizer, Alcobendas (Madrid), 2Department of Urology, Hospital General Universitario de Valencia, Valencia, 3Depa...

Full description

Bibliographic Details
Main Authors:	Peral C, Sánchez-Ballester F, García-Mediero JM, Ramos J, Rejas J
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-09-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	Antimuscarinic Fesoterodine Flexible-dose Overactive bladder
Online Access:	https://www.dovepress.com/cost-effectiveness-analysis-of-fesoterodine-flexible-dose-in-newly-dia-peer-reviewed-article-CEOR

Similar Items

Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
by: Heesakkers J, et al.
Published: (2017-10-01)

A pilot study of the use of fesoterodine in the management of men with refractory overactive bladder symptoms after surgery for bladder outlet obstruction
by: Bilal Chughtai, et al.
Published: (2015-03-01)

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
by: Castro-Diaz David, et al.
Published: (2012-07-01)

Solifenacin and Tolterodine are Equally Effective in the Treatment of Overactive Bladder Symptoms
by: Chen-Hsun Ho, et al.
Published: (2010-10-01)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
by: Luisa Gracio Ferreira Sartori, et al.
Published: (2023-08-01)

Comparative persistence, switch rates, and predictors for discontinuation of antimuscarinics for overactive bladder: A 10-year nationwide population-based study in Taiwan
by: Hao-Wei Chen, et al.
Published: (2018-01-01)

Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review
by: Vozmediano-Chicharro R, et al.
Published: (2020-08-01)

The experience of using fesoterodine in patients with overactive bladder in the older age group
by: Elena I. Ermakova
Published: (2020-05-01)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
by: Löfling L, et al.
Published: (2019-01-01)

A historical perspective on anticholinergics in overactive bladder (OAB) treatment: “Foundations, current practices, and future prospects”
by: D. Carolina Ochoa, et al.
Published: (2024-12-01)

The effectiveness of intravesical oxybutynin in the management of overactive bladder: a clinical study
by: Shoeb Alahmad, et al.
Published: (2024-12-01)

Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?
by: Ömer Acar, et al.
Published: (2019-06-01)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
by: Yuh-Chen Kuo, et al.
Published: (2023-01-01)

Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials
by: Hann-Chorng Kuo, et al.
Published: (2015-03-01)

Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study
by: Sheng-Fu Chen, et al.
Published: (2022-10-01)

Exploring Concomitant Acetylcholinesterase Inhibitor and Overactive Bladder Anticholinergic Use and Risk of Hospitalization in Medicare and Dual-Eligible Medicare–Medicaid Populations in a Historic Database
by: Jonathan H. Watanabe, et al.
Published: (2023-09-01)

Bladder contractility index changes with short-term antimuscarinic therapy in patients with detrusor overactivity: A placebo controlled randomised study
by: Alka Ashok Bhide, et al.
Published: (2023-12-01)

Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome
by: Megha O. Raj, et al.
Published: (2024-08-01)

Comparison of different types of therapy for overactive bladder: A systematic review and network meta-analysis
by: Peng Liu, et al.
Published: (2022-10-01)

The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine
by: HU Simon, et al.
Published: (2009-03-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)

Differences in bladder neck angles between female patients with overactive bladders and healthy peers
by: Mehmet Yoldas, et al.
Published: (2024-06-01)

Botulinum toxin A for the Treatment of Overactive Bladder
by: Po-Fan Hsieh, et al.
Published: (2016-02-01)

ONABOTULINUM TOXIN-A FOR OVERACTIVE BLADDER
by: Mahmood Shakir Abdulkarim
Published: (2016-12-01)

The Urobiome and Its Role in Overactive Bladder
by: Sangrak Bae, et al.
Published: (2022-09-01)

Effect of caffeine on bladder function in patients with overactive bladder symptoms
by: Supatra Lohsiriwat, et al.
Published: (2011-01-01)

Validated stability-indicating RP-HPLC assay method for fesoterodine fumarate in pharmaceutical products
by: Onur PINARBASLI, et al.
Published: (2023-05-01)

Mediterranean Diet and Overactive Bladder
by: Yunus Erol Bozkurt, et al.
Published: (2022-06-01)

Clinical Experience of the Use of Tolterodine in Patients with Overactive Bladder at Siriraj Hospital
by: Vitaya Titapant, et al.
Published: (2020-08-01)

Impact of overactive bladder on retrograde ejaculation
by: Ahmet Salvarci, et al.

Overactive Bladder during Pregnancy: A Prospective Longitudinal Study
by: Hung-Ju Chen, et al.
Published: (2022-02-01)

Evaluation of quality of life in women with overactive bladder (a survey)
by: F N Makhmejanova
Published: (2014-04-01)

Review of the epidemiology of overactive bladder
by: Eapen RS, et al.
Published: (2016-06-01)

Increased Bladder Wall Thickness in Diabetic and Nondiabetic Women With Overactive Bladder
by: Hakkı Uzun, et al.
Published: (2013-06-01)

Childhood nocturnal enuresis and clinical course of overactive bladder in women
by: Igor V. Kuzmin, et al.
Published: (2024-10-01)

Systematic review and meta-analysis on the association of metabolic syndrome in women with overactive bladder
by: Ana M. Fernández-Alonso, et al.
Published: (2025-12-01)

Establishment of an overactive bladder model in mice
by: Tengfei Lv, et al.
Published: (2023-02-01)

Role of liposome in treatment of overactive bladder and interstitial cystitis
by: Shih-Ya Hung, et al.
Published: (2015-03-01)

Seasonal Variation of Overactive Bladder Symptoms in Female Patients
by: Bum Sik Tae, et al.
Published: (2019-12-01)

Clinical and urodynamic effects of tolterodine in women with an overactive bladder
by: Chiu-Lin Wang, et al.
Published: (2013-09-01)